AIRSCULPT TECHNOLOGIES INC (AIRS)
Health Care · Minimally invasive aesthetic body contouring · NASDAQ
AirSculpt operates a proprietary, minimally invasive body contouring platform that removes fat and tightens skin through 31 treatment centers, competing with traditional liposuction and non-surgical fat reduction while benefiting from rising GLP-1 drug adoption.
What AIRSCULPT TECHNOLOGIES INC does
AirSculpt Technologies operates a proprietary, minimally invasive body contouring procedure that removes fat and tightens skin across targeted body areas without needles, scalpels, stitches, or general anesthesia. The company performs procedures through a network of 31 treatment centers across 20 U.S. states and Canada, offering specialized treatments including the Power BBL (Brazilian butt lift), Up a Cup (breast enhancement), Hip Flip (hourglass contouring), and cellulite reduction via AirSculpt Smooth. Procedures are conducted by surgeons through surgeon-owned Professional Associations, while AirSculpt provides management services and operates the non-clinical assets.
Themes: ["Body contouring / fat reduction","Minimally invasive aesthetic procedures","Skin tightening","Cosmetic fat transfer","Cellulite reduction","Weight loss drug / GLP-1 complementary procedures"]
Fundamentals
- Price$4.33 as of 2026-07-09 close
- Market cap$305M as of 2026-07-10
- 1-year return-22.2% as of 2026-07-09 close
- Net margin-7.4% as of 2026-07-10
- Gross margin+66.1% as of 2026-07-10
- ROE-12.4% as of 2026-07-10
- Debt / equity0.45 as of 2026-07-10
- Revenue growth (YoY)-11.8% as of 2026-07-10
- Revenue CAGR (3y)-3.5% SEC XBRL
- Beta2.41 as of 2026-07-10
Dividend: 1-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Revenue declined 15.8% YoY in 2025 (to $151.8M from $180.4M) and operating margins remain negative, with net loss of $2.4M in Q1 2026","Dependence on surgeon-owned Professional Associations for clinical operations and regulatory compliance across multiple states; corporate practice of medicine restrictions limit direct operational control","Market uncertainty from rapid adoption of weight-loss drugs (GLP-1 agonists) makes long-term demand for body contouring procedures difficult to predict and could impact revenue growth"]
Competitors & peers
- Allergan Aesthetics (AZN aesthetics division)
- Solta Medical (liposuction and body contouring devices)
- Cynosure (cryolipolysis and laser lipolysis)
- SculpSure (laser lipolysis)
- CoolSculpting / Zeltiq (cryolipolysis)
- Traditional liposuction providers and plastic surgery centers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.